Importantly, therapeutic strategies targeting the link between FOXA1 and the AR would be relevant in disease stages where AR signaling continues to be critical and where FOXA1 expression remains high, such as primary prostate cancer and CRPC (Figure 2). The gene discussed is AR; the disease is prostate cancer.